The University of Chicago Header Logo

Connection

Shayan Rayani to Neoplasm, Residual

Back to Details
This is a "connection" page, showing publications Shayan Rayani has written about Neoplasm, Residual.
Shayan Rayani
Connection Strength
0.047
Neoplasm, Residual
  1. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.